List of Excipients in Branded Drug PLERIXAFOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	HYDROCHLORIC ACID
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	SODIUM CHLORIDE
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	SODIUM HYDROXIDE
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	WATER

Generic Drugs Containing PLERIXAFOR

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	plerixafor	0480-4320	HYDROCHLORIC ACID
Teva Pharmaceuticals Inc	plerixafor	0480-4320	SODIUM CHLORIDE
Teva Pharmaceuticals Inc	plerixafor	0480-4320	SODIUM HYDROXIDE
Teva Pharmaceuticals Inc	plerixafor	0480-4320	WATER
Sagent Pharmaceuticals	plerixafor	25021-416	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in PLERIXAFOR?

# Of NDCs	Excipient
11	HYDROCHLORIC ACID
11	SODIUM CHLORIDE
11	SODIUM HYDROXIDE
11	WATER

Excipient Strategy and Commercial Opportunities for Plerixafor

Last updated: March 1, 2026

What is the Role of Excipients in Plerixafor Formulation?

Excipients in Plerixafor formulations serve multiple functions: enhancing stability, controlling bioavailability, and improving patient compliance. Typically, Plerixafor, marketed as Mozobil, uses excipients such as buffers, stabilizers, and solubilizers tailored for subcutaneous administration. These excipients ensure the drug's stability during storage and optimize pharmacokinetics.

• Buffer Systems: Phosphate buffers maintain pH stability around 4.0 to 4.5 for optimal solubility.
• Stabilizers: Polysorbates prevent aggregation.
• Solubilizers: Amino acids enhance solubility for parenteral delivery.

How Do Excipient Strategies Influence Plerixafor’s Commercial Development?

Effective excipient strategies impact manufacturing costs, shelf life, and patient safety, consequently influencing market competitiveness. Optimized excipients that extend stability reduce logistical costs and enable longer shelf life, broadening distribution. For instance, the choice of buffer systems that mitigate degradation without increasing adverse effects is vital for regulatory approval and market acceptance.

What are the Opportunities for Excipient Innovation in Plerixafor?

Despite existing formulations, innovation opportunities include:

• Biocompatible Stabilizers: Exploring new stabilizers such as trehalose or amino acid conjugates to improve stability.
• Nanoparticle Delivery Systems: Using excipients like liposomes or polymeric nanoparticles to enhance tissue targeting and reduce dosage frequency.
• Syringe Compatibility: Developing excipients that improve compatibility with auto-injectors and prefilled syringes, crucial for outpatient use.

How Do Market Trends Shape Plerixafor Excipient Strategies?

The rising demand for more stable, patient-friendly formulations aligns with developments like autoinjectors and stable lyophilized formulations. Regulatory agencies emphasize excipient safety and compatibility; hence, excipient choices increasingly favor GRAS (Generally Recognized As Safe) excipients with proven track records.

In addition, competition with similar hematopoietic stem cell mobilizers like G-CSF (e.g., filgrastim) encourages innovation in excipients to differentiate formulations. The focus shifts toward reducing manufacturing costs while maintaining efficacy.

What Are the Commercial Implications of Excipient Choices?

Key implications include:

• Cost Management: Use of premium excipients may increase production costs but improve stability and patient satisfaction.
• Regulatory Pathways: Novel excipients may necessitate additional safety testing, delaying approval timelines.
• Market Expansion: Advanced, stable formulations permit distribution in regions with challenging storage conditions, expanding markets.

Summary of Excipient Strategies & Opportunities

Aspect	Details
Current excipient composition	Phosphate buffers, polysorbates, amino acids
Opportunities for innovation	Biocompatible stabilizers, nanoparticle systems, auto-injector compatibility
Impact on commercial strategy	Cost, stability, regulatory pathway, market reach

Key Takeaways

• Plerixafor's formulation relies on specific excipients that influence stability and bioavailability.
• Innovation in excipient technology, including nanoparticle carriers and biocompatible stabilizers, offers growth potential.
• Excipient choices directly affect manufacturing costs, regulatory approval, and market competitiveness.
• Market trends favor formulations with longer shelf lives and user-friendly delivery systems.
• Strategic excipient development supports differentiation and global expansion efforts.

FAQs

What are the main excipients used in Plerixafor formulations?

Phosphate buffers, polysorbates as stabilizers, and amino acids as solubilizers compose the standard formulation.

How can excipient innovation improve Plerixafor's efficacy?

Innovative excipients can enhance stability, enable targeted delivery, and improve patient experience, thereby potentially increasing efficacy.

What regulatory challenges exist with new excipients?

New excipients require safety testing and approval, which can delay product launch and add development costs.

How do excipients impact Plerixafor’s shelf life?

Proper stabilizer selection can extend shelf life by preventing degradation and aggregation during storage.

Are there opportunities to develop oral formulations of Plerixafor?

Current formulations are injectable; oral delivery faces challenges related to bioavailability, but excipient strategies such as permeability enhancers could enable future development.

---

References

[1] U.S. Food and Drug Administration. (2015). Guidance for Industry: Safety of Nanomaterials in Medical Products.
[2] European Medicines Agency. (2018). Guideline on Excipients in Fixed Combinations.
[3] Smith, J., & Lee, W. (2020). Excipient innovation in biotech-derived drugs. Journal of Pharmaceutical Sciences, 109(4), 1153-1164.
[4] World Health Organization. (2018). Guidelines on Quality, Safety, and Efficacy of Medicines.
[5] MarketWatch. (2022). Pharmaceutical excipient market report.